Despite its potentially large patient pool, China was not initially included in the development plan for PF-06252616 (domagrozumab), a monoclonal antibody that blocks muscular growth inhibiting protein myostatin, when the rare disease team of Pfizer Inc. sat down to plan the study for the investigational compound.
Pfizer's initial plan was to conduct an assessment for the therapy to treat Becker muscular dystrophy (BMD), a milder type...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)